Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Catharina Svanborg | 32,99 | 73,95 | 2025-09-26 |
| Avanza Pension | 6,28 | 2,20 | 2025-09-26 |
| Nordnet Pensionsförsäkring | 5,89 | 2,00 | 2025-09-26 |
| Nordea Liv & Pension | 4,22 | 1,43 | 2025-09-26 |
| Rolf Karlsson | 3,54 | 1,20 | 2025-09-26 |
| Hans Nygren | 1,75 | 0,60 | 2025-09-26 |
| Henrik Sundin | 1,21 | 0,41 | 2025-11-12 |
| Försäkringsaktiebolaget Skandia | 0,74 | 0,26 | 2025-09-26 |
| Anders Borum | 0,53 | 0,18 | 2025-09-26 |
| Handelsbanken Liv Försäkring AB | 0,52 | 0,17 | 2025-09-26 |
2026-02-13 Interim Report 2026-Q2
2026-05-22 Interim Report 2026-Q3
2026-08-28 Year End Report 2026
2026-11-13 Interim Report 2027-Q1
2026-11-20 Annual General Meeting 2026
